Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model
Channel Therapeutics (NYSE: CHRO) announced positive results from preclinical trials of its NaV1.7 inhibitor nerve block formulations for acute pain. The study demonstrated superior efficacy and duration compared to bupivacaine, the current standard of care. Three out of four formulations showed better efficacy than bupivacaine, with one formulation remaining effective for over four days.
The trials included thermal hyperalgesia and mechanical allodynia tests in rodents, with multiple test arms including placebo, bupivacaine, and four Company formulations. Unlike current nerve block therapies that cause temporary paralysis, the NaV1.7 approach doesn't impact mobility, potentially offering better post-surgical physical therapy options.
The Company is targeting the post-operative global pain market, valued at $2.6 billion in 2023. Results for additional studies on eye drops for various types of eye pain are expected in late January 2025.
Channel Therapeutics (NYSE: CHRO) ha annunciato risultati positivi dai trial preclinici delle sue formulazioni di blocco nervoso inibitori di NaV1.7 per il dolore acuto. Lo studio ha dimostrato una maggiore efficacia e durata rispetto alla bupivacaina, l'attuale standard di cura. Tre su quattro formulazioni hanno mostrato una migliore efficacia rispetto alla bupivacaina, con una formulazione che è rimasta efficace per oltre quattro giorni.
I trial hanno incluso test di iperalgesia termica e allodinia meccanica in roditori, con più bracci di prova che comprendevano placebo, bupivacaina e quattro formulazioni dell'azienda. A differenza delle attuali terapie di blocco nervoso che provocano una paralisi temporanea, l'approccio NaV1.7 non influisce sulla mobilità, offrendo potenzialmente migliori opzioni di fisioterapia post-chirurgica.
L'azienda mira al mercato globale del dolore post-operatorio, valutato 2,6 miliardi di dollari nel 2023. I risultati di ulteriori studi su colliri per vari tipi di dolore oculare sono attesi per la fine di gennaio 2025.
Channel Therapeutics (NYSE: CHRO) anunció resultados positivos de ensayos preclínicos de sus formulaciones de bloqueador nervioso inhibidor de NaV1.7 para el dolor agudo. El estudio demostró una eficacia y duración superiores en comparación con la bupivacaína, el estándar actual de atención. Tres de cuatro formulaciones mostraron mejor eficacia que la bupivacaína, con una formulación que permaneció efectiva por más de cuatro días.
Los ensayos incluyeron pruebas de hiperalgesia térmica y alodinia mecánica en roedores, con múltiples grupos de prueba que incluían placebo, bupivacaína y cuatro formulaciones de la empresa. A diferencia de las terapias de bloqueo nervioso actuales que causan parálisis temporal, el enfoque NaV1.7 no afecta la movilidad, ofreciendo potencialmente mejores opciones de fisioterapia postquirúrgica.
La empresa está apuntando al mercado global del dolor postoperatorio, valorado en $2.6 mil millones en 2023. Se esperan resultados de estudios adicionales sobre gotas para los ojos para varios tipos de dolor ocular a finales de enero de 2025.
Channel Therapeutics (NYSE: CHRO)는 급성 통증을 위한 NaV1.7 억제제 신경 차단 제제의 전임상 시험에서 긍정적인 결과를 발표했습니다. 이 연구는 현재 표준 치료인 부피바카인에 비해 우수한 효능과 지속 시간을 보여주었습니다. 4개의 제형 중 3개가 부피바카인보다 더 나은 효능을 보였으며, 한 제형은 4일 이상 효과를 유지했습니다.
시험에는 설치류에서의 열적 과민증 및 기계적 알로디니아 테스트가 포함되었으며, 위약, 부피바카인 및 회사의 네 가지 제형을 포함한 여러 시험 그룹이 있었습니다. 현재의 신경 차단 요법이 일시적인 마비를 유발하는 것과 달리, NaV1.7 접근법은 이동성을 저해하지 않아 수술 후 물리 치료 옵션을 더 잘 제공할 수 있습니다.
회사는 2023년 26억 달러로 평가되는 수술 후 글로벌 통증 시장을 목표로 하고 있습니다. 다양한 유형의 눈 통증을 위한 안약에 대한 추가 연구 결과는 2025년 1월 말에 발표될 예정입니다.
Channel Therapeutics (NYSE: CHRO) a annoncé des résultats positifs d'essais précliniques pour ses formulations de bloc nerveux inhibiteurs de NaV1.7 pour la douleur aiguë. L'étude a démontré une efficacité et une durée supérieures par rapport à la bupivacaïne, l'actuel standard de soins. Trois des quatre formulations ont montré une meilleure efficacité que la bupivacaïne, une formulation ayant conservé son efficacité pendant plus de quatre jours.
Les essais comprenaient des tests d'hyperalgésie thermique et d'allodynie mécanique chez des rongeurs, avec plusieurs groupes de tests incluant placebo, bupivacaïne et quatre formulations de la société. Contrairement aux thérapies de bloc nerveux actuelles qui provoquent une paralysie temporaire, l'approche NaV1.7 n'affecte pas la mobilité, offrant potentiellement de meilleures options de rééducation postopératoire.
La société vise le marché mondial de la douleur postopératoire, évalué à 2,6 milliards de dollars en 2023. Les résultats d'études supplémentaires sur des collyres pour différents types de douleurs oculaires sont attendus fin janvier 2025.
Channel Therapeutics (NYSE: CHRO) hat positive Ergebnisse aus präklinischen Studien zu seinen NaV1.7-Inhibitoren für die Nervenblockade bei akuten Schmerzen bekannt gegeben. Die Studie zeigte eine überlegene Wirksamkeit und Dauer im Vergleich zu Bupivacain, dem derzeitigen Standard der Behandlung. Drei von vier Formulierungen zeigten eine bessere Wirksamkeit als Bupivacain, wobei eine Formulierung über vier Tage wirksam blieb.
Die Studien umfassten Tests zu thermischer Hyperalgesie und mechanischer Allodynie bei Nagetieren, mit mehreren Prüfarmen, einschließlich Placebo, Bupivacain und vier Firmenformulierungen. Im Gegensatz zu den aktuellen Nervenblocktherapien, die eine vorübergehende Lähmung hervorrufen, beeinflusst der NaV1.7-Ansatz nicht die Mobilität und bietet möglicherweise bessere Optionen für die Physiotherapie nach der Operation.
Das Unternehmen zielt auf den globalen Markt für postoperative Schmerzen, der im Jahr 2023 mit 2,6 Milliarden US-Dollar bewertet wird. Ergebnisse weiterer Studien zu Augentropfen gegen verschiedene Arten von Augenschmerzen werden für Ende Januar 2025 erwartet.
- Three of four formulations demonstrated superior efficacy compared to current standard treatment bupivacaine
- One formulation showed effectiveness for over four days, significantly longer than current treatments
- Product doesn't cause temporary paralysis, allowing better post-surgical therapy options
- Targeting established $2.6 billion post-operative pain market
- Product still in preclinical stage, requiring significant development before commercialization
- One of four formulations failed to show material improvement over existing treatment
Insights
FREEHOLD, N.J., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, (“Channel” or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, today announced that it achieved its endpoints in two pre-clinical in vivo models of the Company’s nerve block formulations for acute pain, showing material improvement over the existing standard of care, bupivacaine, in both efficacy and duration.
“We are very pleased with the results, which potentially demonstrate that nerve blocks with our NaV1.7 inhibitors may be viable options for the treatment of acute and postoperative pain,” stated Dr. Eric Lang, Chief Medical Officer of Channel. “Additionally, we believe this drug has the potential to improve on existing postoperative therapeutic options while opening the door for success with our other programs,” concluded Dr. Lang.
About the trial
The Company performed a thermal hyperalgesia test in rodents with a placebo arm, bupivacaine arm and four arms of the main formulations of the Company’s molecule. The Company also performed a mechanical allodynia test in rodents with the same arms as above. For both models, the drugs were administered as a sciatic nerve block. All four Company formulations showed a depot effect in excess of four days, an improvement over bupivacaine, the current standard of care.
Results
The results of the thermal hyperalgesia results are shown in the chart below. After thirty minutes, three of the four formulations showed materially better efficacy than bupivacaine, with each of the three being statistically superior to placebo for more than two days longer than bupivacaine. One of the formulations remained statistically superior to placebo for more than four days. Further, as NaV1.7 does not have an impact on mobility, this approach may offer a better option for post-surgical physical therapy as current nerve block therapies cause temporary paralysis in the affected area.
Similarly for the mechanical allodynia test results, three of the four formulations showed statistically better efficacy for a longer duration of time than bupivacaine. The mechanical allodynia test is shorter in duration, reflecting the subject’s innate swift recovery rate to surgical incisions. Nonetheless, the results mirrored the successful results set forth with the thermal hyperalgesia test.
“These results support our belief that NaV1.7 is a potent and effective target for the development of drugs for the treatment of pain,” stated Frank Knuettel II, Chief Executive Officer of Channel. “With these results, investors should feel encouraged that we have a strong development path towards successfully launching drugs with considerable market opportunities,” Mr. Knuettel concluded.
According to BioSpace, the post-operative global pain market was valued at
Results are expected for the studies conducted on the Company’s eye drops for the treatment of various types of eye pain – including severe dry eye, corneal abrasions, surgical intervention and other indications – in late January 2025.
About Channel
Channel Therapeutics Corporation is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The Company’s initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic pain, acute and chronic eye pain and post-surgical nerve blocks. For company updates and to learn more about Channel, visit www.channeltherapeutics.com or follow us on social media.
Forward-Looking Statements
This press release contains forward-looking statements regarding the Company’s current expectations. These forward-looking statements include, without limitation, references to the Company’s expectations regarding (i) the Company’s belief that nerve blocks with its NaV1.7 inhibitors may be viable options for the treatment of acute and postoperative pain, (ii) the Company’s belief the Company’s NaV1.7 inhibitor has the potential to improve on existing postoperative therapeutic options while opening the door for success with the Company’s other programs, (iii) the Company’s belief that the NaV1.7 inhibitor may offer a better option for post-surgical physical therapy as compared to bupivacaine, (iv) the Company’s belief that investors should feel encouraged that the Company has a strong development path towards successfully launching drugs with considerable market opportunities, and (iv) the timing of expected results on the Company’s eye drops for the treatment of various types of eye pain. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ materially from those set forth in such forward-looking statements include, but are not limited to, risks and uncertainties related to there being no guarantee that the trading price of the Company’s Common Stock will be indicative of the Company’s value or that the Company’s Common Stock will become an attractive investment in the future. These and other risks and uncertainties are described more fully in in our filings with the U.S. Securities and Exchange Commission. The information in this press release is provided only as of the date of this press release, and we undertake no obligation to update any forward-looking statements contained in this press release based on new information, future events, or otherwise, except as required by law.
Channel Media and Investor Inquires:
For Investor Inquiries:
Mike Moyer
Managing Director, LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com
FAQ
What were the key findings of Channel Therapeutics' (CHRO) preclinical trials for its pain treatment?
How does Channel Therapeutics' (CHRO) NaV1.7 inhibitor differ from current nerve block treatments?
What is the market potential for Channel Therapeutics' (CHRO) post-operative pain treatment?
When will Channel Therapeutics (CHRO) release results for its eye pain treatment studies?
